Citius Pharmaceuticals, Inc. financial data

Symbol
CTXR on Nasdaq
Location
Cranford, NJ
Fiscal year end
30 September
Latest financial report
10-K - Q3 2025 - 23 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 47% % -75%
Quick Ratio 36% %
Debt-to-equity 86% % 262%
Return On Equity -23% % 44%
Return On Assets -20% % 27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20,762,917 shares 169%
Common Stock, Shares, Outstanding 18,067,744 shares 149%
Entity Public Float $11,390,000 USD
Common Stock, Value, Issued $18,068 USD 149%
Weighted Average Number of Shares Outstanding, Basic 11,065,225 shares 64%
Weighted Average Number of Shares Outstanding, Diluted 11,065,225 shares 64%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $9,156,474 USD -95%
General and Administrative Expense $18,532,843 USD 1.6%
Operating Income (Loss) $38,525,608 USD 8.3%
Nonoperating Income (Expense) $157,701 USD -105%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $38,683,309 USD 0.43%
Income Tax Expense (Benefit) $144,000 USD 0%
Net Income (Loss) Attributable to Parent $11,511,505 USD -35%
Earnings Per Share, Basic -3.38 USD/shares 43%
Earnings Per Share, Diluted -3.38 USD/shares 43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,252,290 USD 31%
Inventory, Net $22,286,693 USD 170%
Assets, Current $27,934,473 USD 96%
Property, Plant and Equipment, Net $275 USD -90%
Operating Lease, Right-of-Use Asset $818,694 USD 232%
Goodwill $9,346,796 USD 0%
Other Assets, Noncurrent $102,184,858 USD 0%
Assets $130,938,025 USD 12%
Accounts Payable, Current $13,693,692 USD 178%
Employee-related Liabilities, Current $3,292,447 USD 48%
Accrued Liabilities, Current $4,190,253 USD 24509%
Liabilities, Current $44,914,740 USD 25%
Deferred Income Tax Liabilities, Net $7,770,760 USD 16%
Operating Lease, Liability, Noncurrent $724,925 USD 3301%
Liabilities $53,410,425 USD 26%
Retained Earnings (Accumulated Deficit) $238,804,129 USD -19%
Stockholders' Equity Attributable to Parent $67,550,178 USD -3.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $77,527,600 USD 4.6%
Liabilities and Equity $130,938,025 USD 12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,725,852 USD 23%
Net Cash Provided by (Used in) Financing Activities $2,574,051 USD
Common Stock, Shares Authorized 250,000,000 shares 1462%
Common Stock, Shares, Issued 18,067,744 shares 149%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,252,290 USD 31%
Deferred Tax Assets, Valuation Allowance $66,147,000 USD 23%
Operating Lease, Liability $813,273 USD 209%
Lessee, Operating Lease, Liability, to be Paid $987,187 USD 259%
Operating Lease, Liability, Current $88,348 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year Two $232,827 USD 985%
Lessee, Operating Lease, Liability, to be Paid, Year One $171,280 USD -33%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) $264,240 USD 84%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $173,914 USD 1294%
Lessee, Operating Lease, Liability, to be Paid, Year Three $237,686 USD
Deferred Tax Assets, Operating Loss Carryforwards $48,987,000 USD 23%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $242,545 USD
Additional Paid in Capital $306,336,239 USD 13%
Deferred Tax Assets, Net of Valuation Allowance $224,000 USD 234%
Share-based Payment Arrangement, Expense $10,836,291 USD 0%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%